Biotechnology Assets S.A. (MC:BST) — Market Cap & Net Worth
Market Cap & Net Worth: Biotechnology Assets S.A. (BST)
Biotechnology Assets S.A. (MC:BST) has a market capitalization of $13.52 Million (€11.57 Million) as of May 6, 2026. Listed on the MC stock exchange, this Spain-based company holds position #26104 globally and #194 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biotechnology Assets S.A.'s stock price €0.26 by its total outstanding shares 71364339 (71.36 Million). Analyse Biotechnology Assets S.A. operating cash flow efficiency to see how efficiently the company converts income to cash.
Biotechnology Assets S.A. Market Cap History: 2015 to 2026
Biotechnology Assets S.A.'s market capitalization history from 2015 to 2026. Data shows change from $173.06 Million to $21.69 Million (-21.11% CAGR).
Biotechnology Assets S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biotechnology Assets S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
9.29x
Biotechnology Assets S.A.'s market cap is 9.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $173.06 Million | $1.05 Million | -$192.60K | 164.76x | N/A |
| 2016 | $149.50 Million | $1.31 Million | -$1.14 Million | 113.93x | N/A |
| 2017 | $143.25 Million | $2.39 Million | -$73.39K | 59.97x | N/A |
| 2018 | $80.28 Million | $23.32 Million | -$16.69 Million | 3.44x | N/A |
| 2019 | $98.07 Million | $41.83 Million | -$10.08 Million | 2.34x | N/A |
| 2020 | $26.72 Million | $2.52 Million | -$8.61 Million | 10.59x | N/A |
| 2021 | $22.07 Million | $3.09 Million | -$3.01 Million | 7.15x | N/A |
| 2022 | $19.19 Million | $2.61 Million | -$1.94 Million | 7.34x | N/A |
| 2023 | $33.04 Million | $3.91 Million | $1.57 Million | 8.45x | 20.99x |
| 2024 | $23.36 Million | $2.51 Million | -$2.92 Million | 9.29x | N/A |
Competitor Companies of BST by Market Capitalization
Companies near Biotechnology Assets S.A. in the global market cap rankings as of May 6, 2026.
Key companies related to Biotechnology Assets S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Biotechnology Assets S.A. Historical Marketcap From 2015 to 2026
Between 2015 and today, Biotechnology Assets S.A.'s market cap moved from $173.06 Million to $ 21.69 Million, with a yearly change of -21.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €21.69 Million | +32.65% |
| 2025 | €16.35 Million | -30.00% |
| 2024 | €23.36 Million | -29.29% |
| 2023 | €33.04 Million | +72.17% |
| 2022 | €19.19 Million | -13.04% |
| 2021 | €22.07 Million | -17.42% |
| 2020 | €26.72 Million | -72.75% |
| 2019 | €98.07 Million | +22.16% |
| 2018 | €80.28 Million | -43.96% |
| 2017 | €143.25 Million | -4.18% |
| 2016 | €149.50 Million | -13.61% |
| 2015 | €173.06 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Biotechnology Assets S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.52 Million USD |
| MoneyControl | $13.52 Million USD |
| MarketWatch | $13.52 Million USD |
| marketcap.company | $13.52 Million USD |
| Reuters | $13.52 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biotechnology Assets S.A.
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VA… Read more